Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aleniglipron Pharmacokinetics in Hepatic Impairment
NCT07872033Phase 1Not yet recruiting
- Sponsor
- Gasherbrum Bio
- Start
- Oct 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of aleniglipron in obesity and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Gasherbrum Bio. Primary endpoints: Area Under the Curve from Time Zero to Last Quantifiable Concentration, Area Under the Curve from Time Zero to Infinity and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
aleniglipron
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07872033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07872033.